

Beth E. Borowsky, et al.
U.S. Serial No: Not Yet Known
(§371 National Stage Application
of PCT/US00/14654, filed May 26, 2000)
Filed: Herewith
Page 4

insert the ATCC Patent Deposit Designation Numbers, and amended claim 1. Accordingly, upon entry of this Amendment, claims 1-15, and 19-37 will be pending and under examination.

Applicants maintain that the amendment to claim 1 raises no issue of new matter. Support for amended claim 1 may be found inter alia in the specification, as originally-filed, at page 12, lines 3-4; page 29, lines 6-10; page 41, lines 23-29; page 51, lines 19-20; page 51, lines 22-24; page 51, line 30 through page 52, line 2; page 75, lines 5-17; page 77, lines 1-5; page 136, lines 1-3; page 137, lines 6-9; page 137, lines 24-27; and Table 4.

Applicants have amended the specification to insert the ATCC Patent Depository No. PTA-1806 and ATCC Patent Depository No. PTA-1807, respectively. Applicants maintain that the amendments to the specification raise no issue of new matter and respectfully request that this amendment be entered. Applicants attach a copy of the ATCC Patent Deposit Designation Numbers hereto as **Exhibit 2**.

Sequence Listing

The Sequence Listing in the subject application is identical to the Sequence Listing in the parent of the subject application, namely PCT International Application No. PCT/US00/14654, filed May 26, 2000. Applicants attach herewith copies of the paper copy of the Sequence Listing (18 pages) and the Statement In Accordance With 37 C.F.R. §1.821(f) which were filed with PCT International Application No. PCT/US00/14654 on May 26, 2000.

Marked-up Version of the Amendments

Additions to the text are indicated by underlining; deletions are indicated by square brackets.

In the specification:

The paragraph on page 54, lines 10-17 was replaced with the following paragraph:

--In one embodiment, the mammalian cell line is the 293 cell line designated 293-ratSNORF33-31. This cell line was deposited on [May __, 2000] May 3, 2000, with the American Type Culture collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and was [accorded _____] accorded ATCC Patent Deposit Designation No. PTA-1806.--

The paragraph on page 54, lines 19-26 was replaced with the following paragraph:

--In one embodiment, the mammalian cell line is the CHO cell line designated CHO-ratSNORF33-7. This cell line was deposited on [May __, 2000] May 3, 2000, with the American Type Culture collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and was [accorded _____] accorded ATCC Patent Deposit Designation No. PTA-1807.--

In the Claims:

- 1. (Amended) An isolated nucleic acid encoding a mammalian SNORF33 receptor[.], wherein the mammalian SNORF33 receptor has the amino acid sequence of the human SNORF33 receptor (SEQ ID NO: 6) or a sequence having above 75% amino acid sequence identity thereto and is activated by any of tyramine, tryptamine, or β -phenylethylamine.--
- 33. (Amended) The CHO cell of claim 32 designated CHO-ratSNORF33-7 [(ATCC Patent Depository No. _____)] (ATCC Patent Deposit Designation No. PTA-1807).--
- 34. (Amended) The 293 cell of claim 32 designated 293-ratSNORF33-731 [(ATCC Patent Depository No. _____)] (ATCC Patent Deposit Designation No. PTA-1806).--

Beth E. Borowsky, et al.
U.S. Serial No: Not Yet Known
(§371 National Stage Application
of PCT/US00/14654, filed May 26, 2000)
Filed: Herewith
Page 5

In accordance with 37 C.F.R. §1.821 (e), please use the computer readable form filed in PCT International Application No. PCT/US00/14654 on May 26, 2000 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the Sequence Listing that will be used for the instant application.

Accordingly, applicants respectfully request that the Amendment be entered.

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following disclosures which are listed on the attached Form PTO-1449 (**Exhibit 3**) and which were previously cited in connection with the prosecution of U.S. Serial Nos. 09/413,433 or PCT International Application No. PCT/US00/14654 from which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement:

1. European Patent Application EP 0859055 A1, published August

Beth E. Borowsky, et al.
U.S. Serial No: Not Yet Known
(\$371 National Stage Application
of PCT/US00/14654, filed May 26, 2000)
Filed: Herewith
Page 6

19, 1998;


2. UK Patent Application 2,312,211, published October 22,
1997;

3. Bunzow, et al. (Locus AF200627, GenEmbl, 2000);

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the \$546.00 filing fee for the subject application, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if additional any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400